2-(4-trifluoromethylphenyl)-5-methyl-1,3,4-oxadiazole | 497946-53-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-trifluoromethylphenyl)-5-methyl-1,3,4-oxadiazole
• 英文别名: 2-methyl-5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazole；2-methyl-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazole
• CAS: 497946-53-9
• 化学式: C₁₀H₇F₃N₂O
• 分子量: 228.174
• InChiKey: DLMSMINOJJJECX-UHFFFAOYSA-N

物化性质

• 沸点：
  280.5±50.0 °C(Predicted)
• 密度：
  1.313±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(4-trifluoromethylphenyl)-5-methyl-1,3,4-oxadiazole 在 2,2,6,6-tetramethylpiperidinyl-lithium 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 (S)-2-{(R)-2,2-Dimethyl-1-[5-(4-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-propoxycarbonylamino}-hexanoic acid methyl ester
  参考文献：
  名称：

  P2–P3 conformationally constrained ketoamide-based inhibitors of cathepsin K

  摘要：

  An orally bioavailable series of ketoamide-based cathepsin K inhibitors with good pharmacokinetic properties has been identified. Starting from a potent inhibitor endowed with poor drug properties, conformational constraint of the P(2)-P(3) linker and modifications to P(1') elements led to an enhancement in potency, solubility, clearance, and bioavailability. These optimized inhibitors attenuated bone resorption in a rat TPTX hypocalcemic bone resorption model.

  DOI：

  10.1016/j.bmcl.2005.05.062
• 作为产物：
  描述：

  4-(三氟甲基)亚苯基肼 、 原乙酸三乙酯 以 xylene 为溶剂， 生成 2-(4-trifluoromethylphenyl)-5-methyl-1,3,4-oxadiazole
  参考文献：
  名称：

  P2–P3 conformationally constrained ketoamide-based inhibitors of cathepsin K

  摘要：

  An orally bioavailable series of ketoamide-based cathepsin K inhibitors with good pharmacokinetic properties has been identified. Starting from a potent inhibitor endowed with poor drug properties, conformational constraint of the P(2)-P(3) linker and modifications to P(1') elements led to an enhancement in potency, solubility, clearance, and bioavailability. These optimized inhibitors attenuated bone resorption in a rat TPTX hypocalcemic bone resorption model.

  DOI：

  10.1016/j.bmcl.2005.05.062

文献信息

• Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors
  申请人：BASF SE

  公开号：US20140323305A1

  公开（公告）日：2014-10-30

  The present invention relates to the use of strobilurine type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, to plant health applications, and to seeds coated with at least one such compound.

  本发明涉及使用式I的蘑菇酸类化合物以及其N-氧化物和盐来对抗含有对Qo抑制剂产生耐药性的线粒体细胞色素b基因突变的植物病原真菌，以及对抗这类真菌的方法。该发明还涉及新颖的化合物、制备这些化合物的方法、包含至少一种这样的化合物的组合物、植物健康应用以及至少一种这样的化合物包被的种子。
• Microwave promoted one-pot synthesis of 2-aryl substituted 1,3,4-oxadiazoles and 1,2,4-oxadiazole derivatives using Al3+-K10 clay as a heterogeneous catalyst
  作者：Dhanusu Suresh、Kuppusamy Kanagaraj、Kasi Pitchumani

  DOI：10.1016/j.tetlet.2014.05.004

  日期：2014.7

  An efficient, inexpensive method is developed for the one-pot synthesis of 2-aryl substituted 1,3,4-oxadiazoles and 1,2,4-oxadiazoles starting from acid hydrazides and trimethyl orthoformate under solvent-free, microwave conditions using a reusable Al3+-K10 montmorillonite clay as a heterogeneous catalyst. The novelty of the present study lies in the synthesis of oxadiazole and benzimidazole moieties

  开发了一种有效，廉价的方法，可在无溶剂的微波条件下，从酰肼和原甲酸三甲酯开始，一锅法合成2-芳基取代的1,3,4-恶二唑和1,2,4-恶二唑Al 3+ -K10蒙脱土作为非均相催化剂。本研究的新颖之处在于在温和的条件下，由易得的前体和催化剂以一锅法高收率合成恶二唑和苯并咪唑部分。
• [EN] ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS<br/>[FR] DERIVES D'ALPHA-CETOAMIDE UTILISES EN TANT QU'INHIBITEURS DE LA CATHEPSINE K
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003013518A1

  公开（公告）日：2003-02-20

  Biaryl ketoamide derivatives (I), which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such biaryl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.

  本文描述了有用于作为蛋白酶K抑制剂的双芳基酮酰胺衍生物(I)。所述的发明还包括制备这种双芳基酮酰胺衍生物的方法，以及在治疗与增强骨转换相关的疾病，包括骨质疏松症，最终可能导致骨折的方法。
• Alpha-ketoamide derivatives as cathepsin k inhibitors
  申请人：Barrett David Gene

  公开号：US20050107616A1

  公开（公告）日：2005-05-19

  Biaryl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such biaryl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.

  本文介绍了用作猫hepsin K抑制剂的联苯基酮酰胺衍生物。所述发明还包括制备这种联苯基酮酰胺衍生物的方法，以及将其用于治疗与增强骨转换有关的疾病，包括骨质疏松症，该疾病最终可能导致骨折的方法。
• Factor XIa Inhibitors
  申请人：OGAWA Anthony

  公开号：US20160046581A1

  公开（公告）日：2016-02-18

  The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.

  本发明提供了一种化合物（I）及包含一种或多种该化合物的制药组合物，以及使用该化合物治疗或预防血栓、栓塞、高凝状态或纤维化变化的方法。